GLP-1 receptor agonists are licensed in the UK for type 2 diabetes and weight management, including semaglutide, dulaglutide, and liraglutide These medications reduce HbA1c by approximately 1.01.5 percentage points and improve both fasting and post-meal glucose levels Weight loss associated with GLP-1 therapy can lead to secondary improvements in insulin resistance, particularly through reduction of visceral fat Common side effects include gastrointestinal symptoms such as nausea, vomiting, and diarrhoea, which typically diminish over several weeks NICE recommends continuation only if patients achieve at least 1.0 percentage point HbA1c reduction within six months of treatment initiation Patients with diabetic retinopathy require close monitoring, and GLP-1 medications should be discontinued at least two months before planned pregnancy Table of Contents What Are GLP-1 Receptor Agonists and How Do They Work

Be honest and transparent about your medical history, current medications, and any concerns or questions you may have
The drug manufacturer advises keeping Wegovy in its original carton to protect it from light
Hence, the rising prevalence of obesity is likely to affect market growth by increasing the demand for GLP-1 receptor agonists
"I think it's absolutely great." He said he did not want compounding to be painted in a negative light, and would not stop using the product unless there was a strong warning from authorities
Primary endpoint: Mean change in A1C from baseline at Week 40